Theravance Biopharma Inc reports results for the quarter ended in September - Earnings Summary

Theravance Biopharma

08/11/2022 01:54

* Theravance Biopharma Inc  TBPH.OQ  reported quarterly
adjusted
earnings of $12.14​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 18 cents per share.
    * Revenue fell 5.6% to $12.45 million from a year ago;
analysts
expected $11.81 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was
$12.14​.
    * The mean earnings estimate of analysts had fallen by
about 47.2%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Theravance Biopharma Inc shares had fallen by 1.8% this
quarter and lost 9.9% so far this year.
    * The company reported quarterly net income of $916.63
million.
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $11.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 01:54 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.18          12.14          Beat
 Jun. 30 2022      0.11           -0.09          Missed
 Mar. 31 2022      -0.11          -0.22          Missed
 Dec. 31 2021      -0.33          -0.43          Missed